Irfan Vardarli
Overview
Explore the profile of Irfan Vardarli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Weber M, Binse I, Oebbecke K, Brandenburg T, Herrmann K, Theurer S, et al.
BMC Endocr Disord
. 2021 Aug;
21(1):161.
PMID: 34376175
Aims: In contrast to all prior AJCC/TNM classifications for differentiated thyroid cancer (DTC) the 8th edition does not take minimal extrathyroidal extension (M-ETE) into consideration for local tumor staging. We...
12.
Vardarli I, Weber M, Rischpler C, Fuhrer D, Herrmann K, Weidemann F
J Clin Med
. 2021 Jul;
10(14).
PMID: 34300196
Fabry disease is a multisystem X-linked lysosomal storage disorder caused by a mutation in the alpha-galactosidase A gene. Deficiency or reduced activity of alpha-galactosidase A (GLA) is leading to progressive...
13.
Vardarli I, Weber M, Weidemann F, Fuhrer D, Herrmann K, Gorges R
Endocr Connect
. 2021 Feb;
10(3):358-370.
PMID: 33638941
Objective: The usefulness of routine calcitonin measurement for early detection of medullary thyroid carcinoma (MTC) in patients with nodular thyroid disease (NTD) has been investigated in various studies. Recently, a...
14.
Vardarli I, Rischpler C, Herrmann K, Weidemann F
Ther Clin Risk Manag
. 2020 Jul;
16:551-558.
PMID: 32606714
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by absence or deficient activity of α-galactosidase A (α-Gal A) due to mutations in the α-galactosidase A gene (), leading...
15.
Aksoy M, Yilmaz G, Vardarli I, Akkoyun I
J Ocul Pharmacol Ther
. 2020 May;
36(8):629-635.
PMID: 32460600
This study aims to compare subfoveal choroidal thicknesses (SFCTs) after intravitreal dexamethasone (IVD) or intravitreal aflibercept (IVA) treatment in patients with persistent diabetic macular edema (DME) unresponsive to intravitreal ranibizumab...
16.
Vardarli M, Hammes H, Vardarli I
Turk J Med Sci
. 2015 Jan;
44(6):1010-20.
PMID: 25552155
Background/aim: Insulin sensitivity and β-cell function during Ramadan fasting in healthy male subjects have not been investigated so far. We assessed the changes of these and other metabolic parameters to...
17.
Nauck M, Vardarli I
J Diabetes Investig
. 2014 May;
1(1-2):24-36.
PMID: 24843405
Unlabelled: Aims/Introduction: To compare clinical consequences of using inretin-based medications versus conventional antidiabetic agents as add-on to metformin in case of monotherapy failure in patients with type 2 diabetes. Materials...
18.
Vardarli I, Arndt E, Deacon C, Holst J, Nauck M
Diabetes
. 2013 Nov;
63(2):663-74.
PMID: 24186866
Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degradation of incretin hormones (glucagon-like peptide 1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]), whereas metformin may increase GLP-1 levels. We examined, in a four-period crossover...
19.
Mentis N, Vardarli I, Kothe L, Holst J, Deacon C, Theodorakis M, et al.
Diabetes
. 2011 Feb;
60(4):1270-6.
PMID: 21330636
Objective: The incretin glucagon-like peptide 1 (GLP-1) exerts insulinotropic activity in type 2 diabetic patients, whereas glucose-dependent insulinotropic polypeptide (GIP) no longer does. We studied whether GIP can alter the...
20.
Vardarli I, Nauck M, Kothe L, Deacon C, Holst J, Schweizer A, et al.
J Clin Endocrinol Metab
. 2011 Jan;
96(4):945-54.
PMID: 21239518
Background And Aims: Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect...